These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 20977290)

  • 1. A biorelevant dissolution stress test device - background and experiences.
    Garbacz G; Klein S; Weitschies W
    Expert Opin Drug Deliv; 2010 Nov; 7(11):1251-61. PubMed ID: 20977290
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Investigation of dissolution behavior of diclofenac sodium extended release formulations under standard and biorelevant test conditions.
    Garbacz G; Weitschies W
    Drug Dev Ind Pharm; 2010 May; 36(5):518-30. PubMed ID: 19877827
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Irregular absorption profiles observed from diclofenac extended release tablets can be predicted using a dissolution test apparatus that mimics in vivo physical stresses.
    Garbacz G; Wedemeyer RS; Nagel S; Giessmann T; Mönnikes H; Wilson CG; Siegmund W; Weitschies W
    Eur J Pharm Biopharm; 2008 Oct; 70(2):421-8. PubMed ID: 18582568
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dissolution testing of oral modified-release dosage forms.
    Garbacz G; Klein S
    J Pharm Pharmacol; 2012 Jul; 64(7):944-68. PubMed ID: 22686342
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Application of biorelevant dissolution tests to the prediction of in vivo performance of diclofenac sodium from an oral modified-release pellet dosage form.
    Jantratid E; De Maio V; Ronda E; Mattavelli V; Vertzoni M; Dressman JB
    Eur J Pharm Sci; 2009 Jun; 37(3-4):434-41. PubMed ID: 19491035
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Understanding the in vivo performance of enteric coated tablets using an in vitro-in silico-in vivo approach: case example diclofenac.
    Kambayashi A; Blume H; Dressman J
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):1337-47. PubMed ID: 24056057
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biorelevant in-vitro performance testing of orally administered dosage forms.
    Reppas C; Vertzoni M
    J Pharm Pharmacol; 2012 Jul; 64(7):919-30. PubMed ID: 22686340
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of dissolution profiles obtained from nifedipine extended release once a day products using different dissolution test apparatuses.
    Garbacz G; Golke B; Wedemeyer RS; Axell M; Söderlind E; Abrahamsson B; Weitschies W
    Eur J Pharm Sci; 2009 Sep; 38(2):147-55. PubMed ID: 19591927
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The influence of dissolution conditions on the drug ADME phenomena.
    Cascone S; De Santis F; Lamberti G; Titomanlio G
    Eur J Pharm Biopharm; 2011 Oct; 79(2):382-91. PubMed ID: 21515367
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of Dissolution Medium pH and Simulated Gastrointestinal Contraction on Drug Release From Nifedipine Extended-Release Tablets.
    Gao Z; Ngo C; Ye W; Rodriguez JD; Keire D; Sun D; Wen H; Jiang W
    J Pharm Sci; 2019 Mar; 108(3):1189-1194. PubMed ID: 30343136
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Coupling biorelevant dissolution methods with physiologically based pharmacokinetic modelling to forecast in-vivo performance of solid oral dosage forms.
    Otsuka K; Shono Y; Dressman J
    J Pharm Pharmacol; 2013 Jul; 65(7):937-52. PubMed ID: 23738721
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmaceutical applications of AC biosusceptometry.
    Corá LA; Américo MF; Romeiro FG; Oliveira RB; Miranda JR
    Eur J Pharm Biopharm; 2010 Jan; 74(1):67-77. PubMed ID: 19482083
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biopharmaceutical challenges associated with drugs with low aqueous solubility--the potential impact of lipid-based formulations.
    O'Driscoll CM; Griffin BT
    Adv Drug Deliv Rev; 2008 Mar; 60(6):617-24. PubMed ID: 18155800
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Estimating drug solubility in the gastrointestinal tract.
    Dressman JB; Vertzoni M; Goumas K; Reppas C
    Adv Drug Deliv Rev; 2007 Jul; 59(7):591-602. PubMed ID: 17599644
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Study on dissolution in vitro of Zhike Pingchuan sustained-release tablets].
    Li X; Feng Z; Huo W; Li Y; Wang B; Zhu S
    Zhongguo Zhong Yao Za Zhi; 2009 May; 34(10):1216-9. PubMed ID: 19673379
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dissolution testing of orally disintegrating tablets.
    Kraemer J; Gajendran J; Guillot A; Schichtel J; Tuereli A
    J Pharm Pharmacol; 2012 Jul; 64(7):911-8. PubMed ID: 22686339
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Magnetic marker monitoring: high resolution real-time tracking of oral solid dosage forms in the gastrointestinal tract.
    Weitschies W; Blume H; Mönnikes H
    Eur J Pharm Biopharm; 2010 Jan; 74(1):93-101. PubMed ID: 19619649
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In-vitro dissolution methods for controlled release parenterals and their applicability to drug-eluting stent testing.
    Seidlitz A; Weitschies W
    J Pharm Pharmacol; 2012 Jul; 64(7):969-85. PubMed ID: 22686343
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug dissolution: significance of physicochemical properties and physiological conditions.
    Jambhekar SS; Breen PJ
    Drug Discov Today; 2013 Dec; 18(23-24):1173-84. PubMed ID: 24042023
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessing gastrointestinal motility and disintegration profiles of magnetic tablets by a novel magnetic imaging device and gamma scintigraphy.
    Goodman K; Hodges LA; Band J; Stevens HN; Weitschies W; Wilson CG
    Eur J Pharm Biopharm; 2010 Jan; 74(1):84-92. PubMed ID: 19602377
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.